Tixagevimab  (Synonyms: AZD8895)

Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor^[1].

Tixagevimab can be combined with Cilgavimab to form AZD7442. AZD7442 (2, 4 or 16 mg/kg, i.v.) results in a dose-dependent decrease in lung infection titres and viral RNA levels and a significant reduction in infection titers at the 16 mg/kg dose compared to animals at the 2 mg/kg dose in hamsters infected with strain G614 or in hamsters infected with the Omicron variant^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2420564-02-7

Liquid

Colorless to light yellow

[Tixagevimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6(10):1233-1244.  [Content Brief]

  [2]. Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model.